ArticleBiopolymers2025
Elucidating Mechanisms of Gelation, Fiber Assembly, and Stability of Injectable Decellularized Extracellular Matrix Biomaterials.
Article in Biopolymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Decellularized Extracellular Matrix (dECM) in Tendon Regeneration: A Comprehensive Review.Advanced healthcare materials · 2026Review
- Immunomodulatory role of decellularized extracellular matrix in skin wound healing.Materials today. Bio · 2026Review
- Elucidating Mechanisms of Gelation, Fiber Assembly, and Stability of Injectable Decellularized Extracellular Matrix Biomaterials.Biopolymers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Decellularized extracellular matrix (dECM)-based biomaterials have been widely used for their applications in tissue engineering. In particular, pepsin digestion of dECM can be used to generate injectable forms, including ECM hydrogels as well as an intravascularly infusible ECM (iECM). However, fundamental materials characterization of these materials has been limited, and thus little is known about what exactly drives gelation of ECM hydrogels or the conditions for fibril assembly and growth. With this study, we sought to answer a fundamental question on how these materials assemble or gel, as well as a translational question on what storage conditions are suitable for these materials. Here, we used second-harmonic generation and transmission electron microscopy to investigate the mechanism of gelation for ECM hydrogels and the nanofibril assembly of the iECM. Overall, these microscopies revealed the origin and morphology of self-assembly and that type I collagen lateral and longitudinal growth drives ECM hydrogel formation. On the contrary, the iECM preserved the same mechanism for nanofiber assembly without gelation. In terms of translation, ensuring the stability after rehydration is critical for therapeutic injection timing since changes in the material could impact both safety and efficacy. Via microscopy in conjunction with bulk material characterization, we found that dECM formulations are best kept at 4°C for a maximum of 24 h after rehydration in order to maintain their original properties. Overall, this work provides evidence for the type I collagen directed self-assembly within heterogeneous, injectable, decellularized ECM biomaterials and also determines clinically relevant material storage conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.